Table 1.

Clinical characteristics and outcomes of severe COVID-19 patients treated with lopinavir–ritonavir (LPV/r) within 12 days of onset of symptoms

Case No.	Sex	Age	Category of oxygen support	Comorbidity	Symptom onset to LPV/r therapy (days)	Course of LPV/r use (days)	Clinical outcomes	Hospitalisation time (days)
1	M	63	Non-invasive ventilation	None	9	12	Discharge	44
2	M	32	High-flow oxygen	Hepatitis B infection	9	7	Discharge	17
3	M	71	Non-invasive ventilation	None	11	8	Death	N/A
4	M	73	High-flow oxygen	Rheumatoid arthritis	4	10	Discharge	15
5	M	55	High-flow oxygen	Hypertension Haemorrhage	7	12	Discharge	42
6	M	67	High-flow oxygen	None	6	10	Discharge	13
7	M	57	High-flow oxygen	None	10	7	Discharge	45
8	M	77	High-flow oxygen	Gout	12	12	Discharge	29
9	F	75	High-flow oxygen	None	8	14	Discharge	22
10	F	57	Non-invasive ventilation	Hypertension, diabetes	11	11	Discharge	39
11	M	46	High-flow oxygen	Hypertension	12	10	Discharge	11
12	F	65	High-flow oxygen	None	3	12	Discharge	17
13	M	33	High-flow oxygen	None	11	15	Discharge	15
14	F	46	High-flow oxygen	None	5	14	Discharge	17
15	M	61	High-flow oxygen	Diabetes	11	9	Discharge	14
16	F	38	High-flow oxygen	None	2	11	Discharge	13
17	F	57	High-flow oxygen	None	5	17	Discharge	35
18	F	72	High-flow oxygen	None	12	10	Discharge	27
19	M	42	High-flow oxygen	Diabetes	9	12	Discharge	17